Media stories about PharMerica (NYSE:PMC) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PharMerica earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.2252761886935 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

PMC has been the subject of several research reports. Zacks Investment Research downgraded PharMerica from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. ValuEngine raised PharMerica from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $30.50.

Shares of PharMerica (NYSE:PMC) opened at $29.25 on Monday. PharMerica has a fifty-two week low of $22.00 and a fifty-two week high of $29.50. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.58 and a quick ratio of 1.79. The firm has a market capitalization of $910.27, a PE ratio of 15.15, a PEG ratio of 1.27 and a beta of 0.82.

PharMerica (NYSE:PMC) last posted its quarterly earnings data on Thursday, November 9th. The company reported $0.46 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.49 by ($0.03). The company had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $596.80 million. PharMerica had a net margin of 0.83% and a return on equity of 10.94%. analysts anticipate that PharMerica will post 1.92 earnings per share for the current fiscal year.

In other PharMerica news, CEO Gregory S. Weishar sold 521,089 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $29.25, for a total transaction of $15,241,853.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 534,089 shares of company stock valued at $15,243,073. 5.04% of the stock is owned by company insiders.

WARNING: “PharMerica (PMC) Receives Daily News Impact Rating of 0.17” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/18/pharmerica-pmc-receives-daily-news-impact-rating-of-0-17.html.

About PharMerica

Insider Buying and Selling by Quarter for PharMerica (NYSE:PMC)

Receive News & Stock Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related stocks with our FREE daily email newsletter.